Professor Jan Holmgren is one of this year’s recipients of Prince Mahidol’s Award in Public Health - the world’s biggest award in the field of global health. Jan is receiving the award for his ground-breaking research on the development of the world’s first effective drinkable cholera vaccine and for showing that cholera vaccine has the potential to eradicate cholera in developing countries.
The national public tender for the booster of TdaP vaccine (diphtheria, tetanus and pertussis), has now been completed. Scandinavian Biopharma was for the second consecutive period awarded this tender and diTekiBooster will continue to be administered to all adolescents in Sweden 13-14 years old. diTekiBooster was considered to have a medical benefit due to its high content of pertussis toxoid.
Standing out from keen competitions, we are very proud to announce that we were the winner of the “2018 Distributor of the Year” award at AJ Vaccines Summit last week.
Ambassadören presenterade under mötet Sveriges aktiva roll inom Global Hälsa, vilken avgörande roll nya vacciner inom diarréområdet kan spela generellt och hur vacciner även kan minska det överhängande globala hotet från antibiotikaresistens.
During VASE 2018 the Ambassador presented Sweden's strategy in Global Health, the essential and lifesaving role new vaccines play in the field of diarrhoeal disease and how vaccines can reduce the imminent global threat of antibiotic resistance.
Den 12–14 juni arrangeras International Vaccines Against Shigella and ETEC (VASE) i Mexiko City. Under mötet samlas världsledande forskare tillsammans med centrala beslutsfattare från WHO, Bill & Melinda Gates Foundation, PATH och ledande forskningsinstitut för att diskutera vacciner mot diarrésjukdomar orsakade av Shigella och ETEC. Vårt ETEC-vaccin, ETVAX®, är naturligtvis på agendan.
The International Vaccines Against Shigella and ETEC(VASE) Conference will be held on June 12 to 14, in Mexico City, Mexico. The aim of this collaborative, interactive gathering is to accelerate the development and introduction of vaccine to prevent and control diarrheal diseases. Our ETEC-vaccine, ETVAX®, is of course on the agenda when the global development of ETEC vaccines will be discussed
Scandinavian Biopharma continues to expand and strengthen its organization. In April Kyoko Misawa started as Clinical Study Manager at Scandinavian Biopharma’s research subsidiary ETVAX AB. Kyoko has more than 20 years’ experience from the pharmaceutical and life science industry in both Japan and Sweden within the field of diabetes, antibiotic, inflammation and orphan drugs
Scandinavian Biopharma fortsätter att expandera och förstärka sin organisation. I april började Kyoko Misawa som Clinical Study Manager på Scandinavian Biopharma’s forskningsbolag ETVAX AB. Kyoko har mer än 20 års erfarenhet från läkemedels- och Life Science industrin från både Japan och Sverige inom områderna diabetes, antibiotika, inflammation och orphan drugs.
We are very proud to report completion of a large Phase I/II child study in Bangladesh, we were awarded 30 MSEK from Horizon 2020 SME and we kick-started a Phase IIB study on travellers to Benin. We have strengthened our organization and continued to grow our distribution business.
Vi kan se tillbaka på ett fantastiskt år där några av höjdpunkterna var att vi slutförde en fas I/II-barnstudie i Bangladesh på 450 personer, vi beviljades 30 miljoner kronor av Horizon 2020 och på rekordtid startades en fas IIB studie på resenärer till Benin. Vi har dessutom flyttat till nya lokaler, förstärkt vår organisation och fortsatt utveckla vår distributionsverksamhet.
From May 2nd to May 4th, over 500 delegates will gather in Stockholm for the main Travel medicine conference in 2018. The conference has a comprehensive scientific program and delegates mainly from northern Europe meet here to discuss common travel health topics and advances in travel medicine. Key achievements for our ETEC vaccine candidate will be presented during the scientific sessions.
